Evidence map›Paper›PMID 39675783›Full record

ArticleEpilepsia2025

Girdin deficiency causes developmental and epileptic encephalopathy with hippocampal sclerosis and interneuronopathy.

Machiko Iida, Motoki Tanaka, Tsuyoshi Takagi, Tohru Matsuki, Kimihiro Kimura, Kazuki Shibata, Yohei Kobayashi, Yuka Mizutani, Haruki Kuwamura, Keitaro Yamada and 6 more

Abstract read
In one paragraph

Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Machiko IidaDepartment of Disease Model, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.ORCID https://orcid.org/0000-0002-2286-9167
Motoki TanakaDepartment of Disease Model, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.ORCID https://orcid.org/0000-0002-0985-9693
Tsuyoshi TakagiDepartment of Disease Model, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.
Tohru MatsukiDepartment of Cellular Pathology, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.ORCID https://orcid.org/0000-0003-1832-2406
Kimihiro KimuraPharmacology Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Kazuki ShibataPharmacology Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Yohei KobayashiPharmacology Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Yuka MizutaniDepartment of Disease Model, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.
Haruki KuwamuraDepartment of Disease Model, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.
Keitaro YamadaDepartment of Pediatric Neurology, Central Hospital, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.
Hiroki KitauraDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0001-8049-5960
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0003-4244-0277
Mayu SakakibaraDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Naoya AsaiDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-1930-0447
Masahide TakahashiDepartment of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-2803-2683
Masato AsaiDepartment of Disease Model, Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Aichi, Japan.ORCID https://orcid.org/0000-0001-6397-373X

Funding

Adaptable and Seamless Technology Transfer Program through Target-Driven R and D AS251Z02522QAdaptable and Seamless Technology Transfer Program through Target-Driven R and D AS262Z0Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research 19K06464Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research 22K06062)Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (B)(17H04065)Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (C)(25460493Sumitomo Pharma Co., LtdTakeda Science Foundation 2014097381
6 · The paper itself

Abstract

objectiveLoss-of-function mutations in the GIRDIN/CCDC88A gene cause developmental epileptic encephalopathy (DEE) in humans. However, its pathogenesis is largely unknown. Global knockout mice of the corresponding orthologous gene (gKOs) have a preweaning lethal phenotype with growth failure, preventing longitudinal analysis. We aimed to overcome this lethality and elucidate DEE pathogenesis.

methodsWe developed a novel lifelong feeding regimen (NLFR), which consists of providing mash food from postnatal day 14 (P14) until weaning (P28), followed by agar-bound food exclusively after weaning. Videography, electroencephalography (EEG), and histological analyses were performed. Conditional Girdin/Ccdc88a knockout mice (cKOs) of variable lineages (Nestin, Emx1, or Nkx2-1) were generated to identify the region responsible for epilepsy.

resultsUnder the NLFR, gKOs survived beyond 1 year and displayed fully penetrant, robust epileptic phenotypes, including early-onset (P22.3 in average) generalized tonic-clonic seizures (GTCSs) (averaging eight per day), which were completely synchronized with fast rhythms on EEG, frequent interictal electroencephalographic spikes (averaging 430 per hour), and progressive deformation of visceral organs. In addition, gKOs had absence seizures, which were not always time-locked to frequent spike waves on EEG. The frequent GTCSs and interictal spikes in gKOs were suppressed by known antiepileptic drugs. Histologically, bilateral hippocampi in gKOs exhibited congenital cornu-ammonis splitting, granule cell dispersion, and astrogliosis. Furthermore, analysis of conditional knockouts using multiple Cre-deleters identified a defect in the delivery of interneuron precursors from the medial ganglionic eminence into the hippocampal primordium during embryogenesis as a major cause of epileptogenesis. SIGNIFICANCE: These findings give rise to a new approach of lifelong caregiving to overcome the problem of preweaning lethality in animal models. We propose a useful model for studying DEE with hippocampal sclerosis and interneuronopathy. gKOs with NLFR combine the contradictory properties of robust epileptic phenotypes and long-term survivability, which can be used to investigate spontaneous epileptic wave propagation and therapeutic intervention in hippocampal sclerosis.

Indexed as

EpilepsyHippocampusInterneuronsMicrofilament ProteinsVesicular Transport ProteinsAnimalsDisease Models, AnimalElectroencephalographyFemaleHippocampal SclerosisMaleMiceMice, KnockoutSclerosisMicrofilament ProteinsVesicular Transport Proteinsanimal modelmesial temporal lobe epilepsymigration defectNkx2‐1parvalbumin‐interneuron

Identifiers

PMID39675783
PMCPMC11827759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.